Modality
ASO
MOA
VEGFi
Target
MET
Pathway
Proteasome
WMSchizophrenia
Development Pipeline
Preclinical
~Apr 2013
→ ~Jul 2014
Phase 1
~Oct 2014
→ ~Jan 2016
Phase 2
~Apr 2016
→ ~Jul 2017
Phase 3
~Oct 2017
→ ~Jan 2019
NDA/BLA
~Apr 2019
→ ~Jul 2020
Approved
Oct 2020
→ May 2031
ApprovedCurrent
NCT03959786
1,723 pts·Schizophrenia
2025-08→2031-05·Active
NCT07558941
2,811 pts·WM
2023-10→2026-09·Not yet recruiting
NCT07923654
246 pts·Schizophrenia
2020-10→TBD·Completed
4,780 total pts2 indications
CompletedCurrentUpcoming
Catalysts (2)
2026-09-085mo awayPh3 Readout· WM
2031-05-235.1y awayPh3 Readout· Schizophrenia
Trial Timeline
Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
Approved
Complet…
Approved
Not yet…
Approved
Active
Catalysts
Ph3 Readout
2026-09-08 · 5mo away
WM
Ph3 Readout
2031-05-23 · 5.1y away
Schizophrenia
ActiveCompletedNot yet recruiting|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03959786 | Approved | Schizophrenia | Active | 1723 | EFS |
| NCT07558941 | Approved | WM | Not yet recr... | 2811 | DAS28 |
| NCT07923654 | Approved | Schizophrenia | Completed | 246 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| Doxasotorasib | AbbVie | Phase 2 | CD38 | |
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| Ceviderotide | Novo Nordisk | Preclinical | IL-13 | |
| Sotosacituzumab | Vertex Pharma | Phase 1 | MET | |
| VRT-6833 | Vertex Pharma | Preclinical | ALK | |
| BGN-8936 | BeiGene | Phase 1/2 | FXIa | |
| Capifutibatinib | Intra-Cellular | Phase 3 | GIP-R | |
| Gozeosocimab | Illumina | Phase 2 | BCMA | |
| RVM-274 | Revolution Medicines | Phase 3 | MET |